Alcon Inc. Ordinary Shares (ALC)
Stock · NYSE · Health Care
$66.18as of 10/16/2026
Price chart
Active signals
ALC Signal Track Record
How signals performed across all stocks →What ALC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | +0.1% | 52% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 27 | +0.4% | 52% | August 14, 2026 |
| Bollinger Band Breakout | 25 | +0.9% | 60% | August 10, 2026 |
| Bollinger Band Breakdown | 19 | +0.7% | 58% | September 4, 2026 |
| Any 20-session window (baseline) | +0.3% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical proced…
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- Employees
- 25,000
- Website
- www.alcon.ch/
Fundamentals
- 1-day range
- $66.04$67.02
- Market cap
- $34.75B
- P/E (trailing)
- 39.24
- P/E (forward)
- 16.69
- EPS (trailing)
- $1.30
- Dividend yield
- 0.32%
- Beta
- 1.10
- Avg. volume
- 1.82M
- Ex-dividend date
- May 6, 2026
- Dividend pay date
- May 7, 2026
Forecasts
16 analyst ratings
Alcon Inc. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- ALCAlcon Inc. Ordinary Shares$66.18▼ 0.60%Market cap $34.75BP/E 39.24$47.8$68.34
- COOThe Cooper Companies Inc. Common Stock$57.94▲ 0.94%Market cap $14.30BP/E 18.44$51.01$89.83
- BLCOBausch + Lomb Corporation Common Shares$16.49▼ 1.02%Market cap $5.84BP/E —$14.39$18.92
- WRBYWarby Parker Inc. Class A Common Stock$23.34▼ 5.08%Market cap $3.31BP/E 365.43$14.96$31
- EYENational Vision Holdings Inc. Common Stock$17.43▼ 1.30%Market cap $1.80BP/E 27.65$14.75$30.02
- STAASTAAR Surgical Company Common Stock$21.27▼ 4.45%Market cap $1.15BP/E 280.68$15.59$35.87
- RXSTRxSight Inc. Common Stock$4.51▼ 3.43%Market cap $251.69MP/E —$4.4$13.22
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALC Alcon Inc. Ordinary Shares | $34.75B | 39.24 | $66.18 | ▼ 0.60% | $47.8$68.34 |
| COO The Cooper Companies Inc. Common Stock | $14.30B | 18.44 | $57.94 | ▲ 0.94% | $51.01$89.83 |
| BLCO Bausch + Lomb Corporation Common Shares | $5.84B | — | $16.49 | ▼ 1.02% | $14.39$18.92 |
| WRBY Warby Parker Inc. Class A Common Stock | $3.31B | 365.43 | $23.34 | ▼ 5.08% | $14.96$31 |
| EYE National Vision Holdings Inc. Common Stock | $1.80B | 27.65 | $17.43 | ▼ 1.30% | $14.75$30.02 |
| STAA STAAR Surgical Company Common Stock | $1.15B | 280.68 | $21.27 | ▼ 4.45% | $15.59$35.87 |
| RXST RxSight Inc. Common Stock | $251.69M | — | $4.51 | ▼ 3.43% | $4.4$13.22 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio.benzinga · 10/16/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- AeraHUB 26 NYC Brings the Decision-Centric Enterprise to LifeYahoo · 10/7/2026
- Barclays Initiates Coverage On Alcon with Equal-Weight Rating, Announces Price Target of $70Benzinga · 10/7/2026
- Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom ReliefYahoo · 9/28/2026
- Alcon (SWX:ALC) Stock Trades Above Fair Value On Earnings PressureYahoo · 9/27/2026
- Bernstein unveils top European medtech stock picks to buy for H2Yahoo · 9/25/2026
- Platauro Metals Corp. - Star Project, UtahYahoo · 9/21/2026
- Cooper Companies: A Little More Compelling At This PriceSeekingAlpha · 9/15/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alcon (ALC) FDA Approves BRYTLY Redness Reliever Eye Drops
The U.S. Food and Drug Administration has cleared Alcon’s BRYTLY Redness Reliever eye drops, a product that promises up to 12 hours of reduced eye redness. The approval adds a new offering to Alcon’s eye‑care portfolio and may support future sales growth. In a separate note, BTIG kept its rating on Alcon but lowered its price target to $74, reflecting a more modest outlook.
Alcon (ALC) FDA Approves BRYTLY Redness Reliever Eye Drops. The U.S. Food and Drug Administration has cleared Alcon’s BRYTLY Redness Reliever eye drops, a product that promises up to 12 hours of reduced eye redness. The approval adds a new offering to Alcon’s eye‑care portfolio and may support future sales growth. In a separate note, BTIG kept its rating on Alcon but lowered its price target to $74, reflecting a more modest outlook.